MeadowBrook Investment Advisors LLC Sells 106 Shares of Stryker Co. (NYSE:SYK)

MeadowBrook Investment Advisors LLC lowered its stake in shares of Stryker Co. (NYSE:SYK) by 2.3% during the fourth quarter, HoldingsChannel reports. The firm owned 4,602 shares of the medical technology company’s stock after selling 106 shares during the quarter. Stryker makes up 1.5% of MeadowBrook Investment Advisors LLC’s investment portfolio, making the stock its 15th largest position. MeadowBrook Investment Advisors LLC’s holdings in Stryker were worth $1,657,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Dunhill Financial LLC increased its holdings in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Stryker during the 3rd quarter worth approximately $36,000. Activest Wealth Management acquired a new position in shares of Stryker during the 4th quarter worth approximately $36,000. Crews Bank & Trust acquired a new position in Stryker in the 4th quarter valued at $39,000. Finally, Hara Capital LLC acquired a new position in Stryker in the 3rd quarter valued at $42,000. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.5 %

Shares of SYK stock opened at $390.52 on Wednesday. The stock has a market cap of $148.88 billion, a price-to-earnings ratio of 50.33, a PEG ratio of 2.98 and a beta of 0.96. The stock has a 50-day moving average of $377.28 and a 200-day moving average of $365.59. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business earned $3.46 earnings per share. On average, equities research analysts forecast that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio is currently 43.30%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

SYK has been the topic of a number of research reports. The Goldman Sachs Group upped their price objective on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday, January 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Barclays upped their price objective on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday. Truist Financial upped their price objective on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Finally, Needham & Company LLC reissued a “buy” rating and set a $442.00 target price on shares of Stryker in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.